Original Article
Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System
N Engl J Med 2008; 358:2457-2467June 5, 2008
- Abstract
Background
There is an urgent need to determine whether oversulfated chondroitin sulfate (OSCS), a compound contaminating heparin supplies worldwide, is the cause of the severe anaphylactoid reactions that have occurred after intravenous heparin administration in the United States and Germany.
Methods
Heparin procured from the Food and Drug Administration, consisting of suspect lots of heparin associated with the clinical events as well as control lots of heparin, were screened in a blinded fashion both for the presence of OSCS and for any biologic activity that could potentially link the contaminant to the observed clinical adverse events. In vitro assays for the activation of the contact system and the complement cascade were performed. In addition, the ability of OSCS to recapitulate key clinical manifestations in vivo was tested in swine.
Results
The OSCS found in contaminated lots of unfractionated heparin, as well as a synthetically generated OSCS reference standard, directly activated the kinin–kallikrein pathway in human plasma, which can lead to the generation of bradykinin, a potent vasoactive mediator. In addition, OSCS induced generation of C3a and C5a, potent anaphylatoxins derived from complement proteins. Activation of these two pathways was unexpectedly linked and dependent on fluid-phase activation of factor XII. Screening of plasma samples from various species indicated that swine and humans are sensitive to the effects of OSCS in a similar manner. OSCS-containing heparin and synthetically derived OSCS induced hypotension associated with kallikrein activation when administered by intravenous infusion in swine.
Conclusions
Our results provide a scientific rationale for a potential biologic link between the presence of OSCS in suspect lots of heparin and the observed clinical adverse events. An assay to assess the amidolytic activity of kallikrein can supplement analytic tests to protect the heparin supply chain by screening for OSCS and other highly sulfated polysaccharide contaminants of heparin that can activate the contact system.
Media in This Article
Figure 1
Effect of OSCS on Kallikrein Activity.Figure 2
OSCS-Induced Activation of Kallikrein in Normal or Factor XII–Depleted Plasma.Article Activity
- Article
In January 2008, health authorities in the United States began receiving reports of clusters of acute hypersensitivity reactions in patients undergoing dialysis that had been occurring since November 2007. Symptoms included hypotension, facial swelling, tachycardia, urticaria, and nausea. Although initial investigations focused on dialysis equipment, an investigation by the Centers for Disease Control and Prevention identified the receipt of heparin sodium for injection (1000 U per milliliter, in 10-ml and 30-ml multidose vials), manufactured by Baxter Healthcare, as a common feature of the cases.1 This finding led Baxter Healthcare to recall, on January 17, 2008, nine lots of heparin sodium for injection. As of April 13, 2008, there were 81 reports of death that involved at least one sign or symptom of an allergic reaction or hypotension in patients receiving heparin since January 1, 2007. However, the fact that allergic symptoms or hypotension were reported does not mean that these were the cause of death in all cases.
After this initial recall, there were continuing reports of allergic-type reactions, including some deaths, after injection of bolus heparin not only in patients undergoing dialysis but also in patients in other clinical settings, such as those undergoing cardiac procedures. On February 28, 2008, Baxter Healthcare recalled all remaining lots and doses of its multidose and single-dose vials of heparin sodium for injection and HEP-LOCK heparin flush products. Since that recall, monitoring by the Food and Drug Administration (FDA) has indicated that, in March 2008, the number of deaths reported in association with heparin usage had returned to baseline levels.2
However, on March 6, a heparin recall was announced in Germany because of a cluster of reactions in patients undergoing dialysis that were linked to a different manufacturer's heparin. On the same day, the FDA posted descriptions of analytic methods on its Web site and recommended that all manufacturers and regulatory authorities screen for a contaminant in heparin.3 This screening revealed widespread contamination of the heparin supply in at least 12 countries.
The contaminant was recently identified as an unusual oversulfated form of chondroitin sulfate (OSCS) representing up to approximately 30% wt/wt in suspect lots of heparin; no other contaminants were observed.4 In addition, dermatan sulfate, a known impurity of heparin, was found in selected samples. Both heparin and chondroitin sulfate are members of the glycosaminoglycan family of complex polysaccharides; heparin contains a disaccharide repeat unit of glucuronic–iduronic acid linked to glucosamine, and chondroitin sulfate contains a disaccharide repeat unit of glucuronic acid linked to galactosamine. Analysis of the contaminant unexpectedly revealed an unusual type of sulfation not found in any natural sources of chondroitin sulfate and indicated that OSCS, containing four sulfates per disaccharide unit, is structurally similar to heparin (see the Supplementary Appendix, available with the full text of this article at www.nejm.org).
However, the biologic link between the presence of the OSCS in heparin and the adverse clinical events remained to be established. Highly charged polyanionic polymers are known to modulate various enzymatic cascades in plasma, affecting coagulation, fibrinolysis, inflammation, and vasculature function.5,6 Bradykinin, a potent vasoactive peptide mediator, is generated through the activation of the contact system of coagulation, which is initiated upon contact of factor XII with a negatively charged surface in the presence of prekallikrein and high-molecular-weight kininogen. Highly sulfated polysaccharides have been shown to serve as a negatively charged surface that can initiate fluid-phase activation of the contact system.5,7 However, initial attempts to recapitulate the adverse responses in experimental models were unsuccessful.8 Without a definitive link between the contaminant and the clinical reactions, concerns remain that the screening tests currently in place may not be adequate to prevent further cases. We therefore set out to identify a biologic basis for a link between OSCS and allergic-type reactions.
Case Report
A representative case involved a 63-year-old woman with a complex medical history, including end-stage renal disease treated with the use of hemodialysis for 7 years, who received heparin intravenously during hemodialysis (5000-U loading dose and 500 U per hour during the procedure) three times weekly. In mid-January 2008, the development of “low blood pressure” was reported, along with nausea and dyspnea, during dialysis. She was treated with normal saline and oxygen (2 liters per minute), and the rates of ultrafiltration and blood flow were slowed. She recovered after 30 minutes, and dialysis was continued. Two days later, she again received intravenous heparin (5000-U loading dose and 500 U per hour) from the same lots of heparin from the same manufacturer (Baxter Healthcare). Immediately after dialysis was initiated, the patient had an anaphylactoid reaction, with a sudden drop in blood pressure (to 65/34 mm Hg), dyspnea, nausea, vomiting, and constitutional symptoms. She was treated with a bolus of normal saline and oxygen (2 liters per minute). Hemodialysis was continued for another hour. The patient continued to feel ill, was admitted to the hospital, and was discharged 2 days later, after recovery. Further dialysis was performed with the use of heparin from another manufacturer.
Methods
Test Samples
Twenty-nine clinical lots of heparin, including 13 associated with clinical adverse events, were procured from the FDA and coded as unknown samples 1 through 29. A laboratory lot of heparin was included as a control. For all analytic and biologic tests, samples were dosed on a weight basis; specific activity of heparin is typically approximately 180 U per milligram. OSCS was purified to homogeneity from a lot of heparin that was known to be contaminated, as previously described.4 Briefly, OSCS-contaminated heparin was subjected to anion-exchange chromatography followed by alcohol precipitation to isolate the contaminant.4 The identity of the contaminant was confirmed by means of multiple orthogonal techniques, including multidimensional nuclear magnetic resonance (NMR), enzymatic digestion followed by high-performance liquid chromatography, and liquid chromatography–mass spectrometry.4 After identification of the contaminant as OSCS, a synthetic standard was generated through chemical sulfonation of chondroitin sulfate A and was exhaustively characterized to ensure authenticity, as previously described.4 The synthetic OSCS was used in spiking experiments to qualify the analytic procedures (especially one-dimensional proton NMR, described below) to determine limits of detection and to establish accurate quantification.4 The limit of detection for this assay was determined to be 0.3% on a weight basis for both dermatan sulfate and OSCS.
Analytic Methods
To ensure accurate identification and quantification of any contaminants and impurities, the 29 coded test samples were subjected to orthogonal analytic techniques. Proton NMR, anion-exchange chromatography, and capillary electrophoresis were used to screen the samples for the presence of OSCS, dermatan sulfate, and other nonheparin components. The levels of OSCS and dermatan sulfate were quantified with the use of a 600-MHz NMR instrument to ensure peak resolution. The details of quantification, as well as a representative spectrum, are given in Figure 1 and Table 1 in the Supplementary Appendix. For samples with unusual patterns, the identity of contaminants or impurities, including OSCS, was confirmed by means of detailed characterization, including the use of multidimensional NMR.4
Amidolytic Activity of Kallikrein
Pooled human plasma or factor XII–depleted plasma (American Diagnostica) was treated with various concentrations of coded test samples of heparin, chondroitin sulfate A, or synthetic OSCS for 5 minutes at 37°C. The amidolytic activity of kallikrein (with a small contribution of factor XII)9 was assessed by adding the S-2302 chromagenic substrate (D-Pro-Phe-Arg-p-nitroaniline [pNA]) for 30 minutes at 37°C, followed by spectrophotometric measurement of the absorbance at 450 nM.
Generation of C3a and C5a
Pooled human EDTA plasma or factor XII–depleted plasma (American Diagnostica) was treated with various concentrations of OSCS-contaminated heparin, control heparin, chondroitin sulfate A, or synthetic OSCS for 30 minutes at 37°C. C3a and C5a activation products of the complement cascade were assayed by means of a sandwich enzyme-linked immunosorbent assay (ELISA), as specified in the manufacturer's instructions (Becton Dickinson and Integrated Biotech Laboratories for C3a and C5a, respectively).
In Vivo Studies
The swine were handled and treated in compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals and the federal Animal Welfare Act. The experimental procedures were performed according to the Institutional Animal Care and Use Committee–approved protocol of the Virginia Polytechnic Institute and State University, Blacksburg. Domestic Yorkshire crossbred swine were of either sex (Virginia Polytechnic Institute and State University) and ranged in weight from 10 to 25 kg. They were initially anesthetized with an intravenous injection of 6 mg of tiletamine hydrochloride per kilogram of body weight and 2.2 mg of xylazine per kilogram, and then a single-lumen silicone catheter was implanted in the left jugular vein of each animal. Adequate anesthesia was maintained throughout the procedure with the administration of supplemental tiletamine. After a 5-minute stabilization period, each pig received an intravenous bolus infusion of 5 mg of the test substance per kilogram (three to six pigs per test substance). All the pigs were continuously monitored for vital signs with the use of an oscillometric blood pressure monitor (Cardell 9401/9403, CAS Medical Systems) for systolic, diastolic, and mean arterial blood pressures, pulse oximetry for pulse and respiratory rates, and a rectal probe for body temperature. At the end of the 60-minute observation period, the animals were euthanized with the use of an intravenous infusion of Fatal Plus (Vortech Pharmaceuticals) at a dose of 0.22 ml per kilogram. Blood samples were collected at baseline and at 5, 10, 20, 40, and 60 minutes and were kept in 5 mM EDTA. Plasma was isolated after centrifugation at 4°C and flash-frozen on dry ice. Frozen samples were thawed at 4°C and assayed for amidolytic activity of kallikrein with the addition of the S-2302 chromagenic substrate (D-Pro-Phe-Arg-pNA), as described above.
Results
Given the association of activation of the contact system with negatively charged polysaccharides, we sought to elucidate whether an in vitro biologic response could be correlated with the identity or levels of contaminant within heparin lots. To this end, we examined the ability of a sample of OSCS-contaminated heparin, containing 19.3% wt/wt OSCS (Table 1 in the Supplementary Appendix), to activate kallikrein amidolytic activity in human plasma (Figure 1AFigure 1
Effect of OSCS on Kallikrein Activity.). The contaminated heparin showed a bell-shaped dose response, which is typical of glycosaminoglycan-mediated responses.5,10 At 2.5 and 25 μg per milliliter, robust activation of kallikrein was found with the contaminated heparin sample but not with a control sample of uncontaminated heparin. These concentrations are in the range of a clinically efficacious concentration of heparin of approximately 1 to 5 μg per milliliter, based on a specific activity of about 180 U per milligram. High concentrations of the OSCS-contaminated heparin (250 μg per milliliter) induced little or no amidolytic activity of kallikrein, suggesting that at this concentration, heparin may inhibit or cause depletion of factor XII, as previously described.7,11,12 This high concentration of heparin also prevented activation of the contact system in response to kaolin, a potent activator (data not shown).To further verify that the contaminant was responsible for the activation of the contact system, OSCS was purified to homogeneity by means of anion-exchange chromatography followed by alcohol precipitation. In addition, an OSCS standard was created through chemical sulfonation of chondroitin sulfate A, to form OSCS.4 The purified contaminant and the OSCS standard were identical, as judged by several orthogonal analytic techniques, including two-dimensional NMR.4 Both the purified contaminant and the synthetic OSCS showed robust activation of kallikrein activity at 0.25 μg and 2.5 μg per milliliter (Figure 1A). The peak activity of the purified contaminant and the synthetic OSCS standard were observed at a level that was approximately an order of magnitude lower than that found for the contaminated heparin sample. This is consistent with the observation that the OSCS constituted approximately 20% of the contaminated sample. Chondroitin sulfate A showed no induction of amidolytic activity.
These results are in good agreement with the observations of Hojima et al.,5 who demonstrated that oversulfated chondroitin, but not chondroitin A, B, or C, can activate the kinin pathway. Heparin also activated the contact system in an in vitro model system involving purified protein components5,13 but did not in plasma,13 suggesting that negative-regulatory factors present in plasma may prevent activation of the contact system by heparin. One such mechanism is the fact that heparin is known to enhance antithrombin III–mediated inhibition of factor XII. Our results indicate that OSCS, in contrast to heparin but similar to dextran sulfate,13 can activate the contact system in plasma.
The 29 heparin samples procured from the FDA, consisting of both suspect heparin lots associated with clinical events as well as control heparin lots, were screened in a blinded fashion for both the presence of OSCS and the ability to activate the contact system (Figure 1B). There was complete correspondence between the presence of detectable amounts of OSCS by one-dimensional proton NMR and the ability of a sample to induce robust amidolytic activity of kallikrein (Figure 1B). The biologic activity was generally characterized as an all-or-none response, with all 13 samples containing detectable levels of OSCS having a positive response at 25 μg or 2.5 μg per milliliter. Sample 11, which contained the highest level of contaminant (27.4%), also showed activity at 0.25 μg per milliliter, whereas Sample 25, which contained the lowest level of contaminant (2.4%), showed only modest activity at 2.5 μg per milliliter. In contrast, there was no association between the level of inducible kallikrein activity and the level of dermatan sulfate (Figure 2 in the Supplementary Appendix), an impurity found in many heparin preparations.
Direct activation of the contact system by the contaminated heparin and the synthetic OSCS standard was confirmed through the use of human plasma depleted of factor XII, the upstream activator of prekallikrein14 (Figure 2Figure 2
OSCS-Induced Activation of Kallikrein in Normal or Factor XII–Depleted Plasma.). The contaminated heparin, the synthetically derived OSCS, and the positive control (the kaolin-containing reagent) all failed to induce the amidolytic activity of kallikrein in factor XII–deficient plasma.We next examined the ability of contaminated heparin to generate C3a and C5a, potent anaphylatoxins derived from complement proteins. Exposure of human plasma to the contaminated heparin, but not to control heparin, induced the production of C5a (Figure 3Figure 3
OSCS and the Generation of Complement-Derived C5a Anaphylatoxin in Human Plasma.). OSCS-induced C5a generation showed a bell-shaped dose response similar to that found for kallikrein activation. Peak C5a activity was observed at 50 μg and 5 μg per milliliter of heparin containing 19.3% OSCS. At 500 μg per milliliter, significant generation of C5a was not observed. Similar results were obtained with the purified OSCS isolated from contaminated heparin and the synthetic OSCS standard, but not with chondroitin sulfate A.Surprisingly, the generation of C5a by OSCS-contaminated heparin was more robust in the presence of EDTA, a Ca2+- and Mg2+-chelating agent, than in the absence of EDTA. The classic and alternative pathways of complement activation are known to be dependent upon Ca2+ and Mg2+, respectively. As expected, EDTA blocked C3a and C5a generation in response to zymosan, a potent activator of the alternative pathway (Figure 4Figure 4
OSCS Induction of Complement-Derived C3a and C5a Anaphylatoxins and Its Relationship to the Contact System.). These results suggested the possibility that OSCS induces the generation of C3a and C5a in a manner that bypasses the C3 and C5 convertases. To determine whether the generation of C3a and C5a was linked to the activation of the contact system, we next examined C3a and C5a generation in factor XII–depleted plasma (Figure 4). As expected, zymosan induced the generation of C3a and C5a in factor XII–depleted plasma, and this activity was inhibited by EDTA. In contrast, neither C3a nor C5a was generated in factor XII–depleted plasma activated with OSCS, suggesting that OSCS bypasses the normal pathways for complement activation in a manner that is dependent on contact activation through factor XII. The generation of C5a could be restored by reconstituting the factor XII–depleted plasma with purified factor XII (Figure 4A). This finding is further supported by the observation that C5a generation induced by OSCS-contaminated heparin can be inhibited by aprotinin, a protease inhibitor of kallikrein but not of factor XIIa (Figure 4A). Crosstalk between the contact system and the complement cascade has been suggested previously.15-18 For example, factor XII has been shown to activate the classical pathway by activating C1.15 It has also been proposed to substitute for factor D in activating the alternative pathway.16 However, in these cases, activation of the complement cascade still occurs through divalent cation–dependent pathways. Kallikrein has been shown to act directly on C5 to generate C5a-like biologic activity.17 Both kallikrein and factor XII can activate the plasminogen pathway leading to the activation of plasmin, which has also been implicated in complement activation.18 Preliminary data suggest that OSCS is unable to induce C5a generation in plasminogen-depleted plasma (data not shown).To identify an appropriate species for in vivo testing of OSCS, a panel of plasma samples were screened for amidolytic activity in response to OSCS-contaminated heparin (Figure 5AFigure 5
In Vitro and In Vivo Activity of OSCS.). Only swine plasma supported robust amidolytic activity of kallikrein in response to kaolin and OSCS-contaminated heparin but not control heparin. In contrast, rabbit, horse, and rat plasma showed moderate-to-robust amidolytic activity in response to kaolin but not to OSCS-contaminated heparin. These findings are consistent with a report that initial attempts to provoke an allergic response with suspect lots of heparin were unsuccessful.8 Similarly, we found that rabbits treated with 5 mg of intravenous OSCS-contaminated heparin per kilogram showed no change in temperature, blood pressure, or heart rate as compared with rabbits treated with control heparin (data not shown). Wiggins19 demonstrated previously that dextran sulfate can induce hypotension in rabbits, but only at a high dose (20 mg per kilogram) and in a manner independent of complement or kinin activation. In contrast, moderate doses of dextran sulfate (5 mg per kilogram) induced a robust hypotensive response in pigs that was dependent on activation of the contact system.20 To test the in vivo activity of OSCS, pigs were treated with a single intravenous dose (5 mg per kilogram) of OSCS-contaminated heparin, control heparin, synthetic OSCS, or chondroitin sulfate A and were monitored for 60 minutes. Animals treated with control heparin and those treated with OSCS-contaminated heparin showed similar anti-Xa activity during the entire 60-minute observation period (activity at 5 minutes, approximately 3 to 4 IU per milliliter) (Figure 4 in the Supplementary Appendix). Animals treated with chondroitin sulfate A or synthetic OSCS showed no anti-Xa activity. These results suggest that any anticoagulant activity of OSCS is mediated through a non–antithrombin III–dependent mechanism. Two of six animals treated with OSCS-contaminated heparin had at least a 30% drop in blood pressure over the first 30 minutes after infusion (Figure 5B). One animal remained in a hypotensive state for more than 15 minutes. In contrast, none of the four animals treated with control heparin showed any substantive changes in blood pressure. The adverse events were more severe in pigs treated with the synthetic OSCS, a result consistent with the greater exposure to OSCS in animals treated with pure OSCS as compared with contaminated heparin containing approximately 20 to 30% OSCS. All three pigs treated with synthetic OSCS showed a profound drop in blood pressure (maximal decrease, 45 to 59%) and a concurrent increase in heart rate within minutes after infusion. One animal had difficulty breathing and became cyanotic after a precipitous drop in blood pressure. The heart rate of a second animal increased from 114 beats per minute to 196 beats per minute within 4 minutes after the infusion of OSCS. The third pig showed a transient but pronounced spike in heart rate with a corresponding drop in blood pressure (Figure 5B). In contrast, none of the three pigs treated with chondroitin sulfate A showed any significant changes in blood pressure or heart rate within the first 30 minutes after drug infusion. Thus, intravenous infusion of OSCS is capable of recapitulating the hallmark cardiovascular features of the reaction in swine. The changes in physiological parameters were mirrored by rapid induction of the amidolytic activity of kallikrein (Figure 5C). Kallikrein activity remained high throughout the observation period, even after the vital functions returned to normal, suggesting depletion of high-molecular-weight kininogen and inactivation of bradykinin by kininases in vivo, as previously shown with dextran sulfate.20 Induction of kallikrein activity was evident in all animals that received OSCS-contaminated heparin, even when no substantive changes in blood pressure were observed. These findings suggest that activation of kallikrein does not always manifest as clinical symptoms, perhaps because of individual variation in control mechanisms that regulate bradykinin activity. Nonetheless, these results also suggest that swine may be an appropriate species in which to assess the potential consequences of OSCS contaminant in cardiovascular and dialysis models as well as in heparin-coated devices.
Discussion
The recent reports of allergic-type serious adverse events in patients receiving heparin and the subsequent detection of widespread contamination have caused intense international concern about the safety of this essential drug. Urgent problems included an immediate and unknown risk to patients' lives, a threat to the supply of a widely used, essential drug, and the need for international cooperation in managing the integrity of a global supply chain. This crisis necessitated an urgent need to both understand the basis for these clinical events and to prevent future occurrences. The development of an analytic assay for OSCS, coupled with the rapid response of manufacturers and regulatory authorities around the world, has undoubtedly limited the harm. However, in the absence of a biologic link between the OSCS contaminant and the adverse events, the adequacy of screening heparin lots to prevent a recurrence is a concern.
Determining whether a link exists between the presence of OSCS and a biologic response required the convergence of two distinct analyses. First, there was a requirement to develop analytic techniques of sufficient sensitivity and specificity to ensure accurate identification and quantification of contaminants or impurities that are present within heparin. Second, there was a requirement to develop a sensitive, clinically appropriate biologic test to determine at what levels, if any, the OSCS would have relevant biologic activity.
With regard to the analytic techniques, a tiered approach was required to ensure effective translation to biologic characteristics. Screening methods were developed to rapidly identify whether heparin lots were contaminated or impure. Then, methods were further developed to enable quantification of the contamination levels. Finally, more sophisticated techniques, such as multidimensional NMR, enabled complete characterization of the contaminant or impurity. This tiered approach was necessitated by the fact that heparin is a polydisperse mixture of glycosaminoglycan chains; orthogonal techniques were therefore required to ensure capture of the other nonheparin components.
Here, we demonstrate that the OSCS present in suspect heparin lots, as well as a synthetic OSCS standard, can directly activate the contact system and induce the generation of C3a and C5a anaphylatoxins in vitro. Moreover, OSCS activates kallikrein in vivo and can induce a profound hypotensive response in pigs, thus providing a potential biologic link between the contaminant and the anaphylactoid reactions seen in affected patients. The finding that hypotension did not develop in all animals treated with OSCS-contaminated heparin, even at a relatively high dose, is consistent with the observation that the majority of patients who received contaminated heparin did not experience an adverse event. However, it is important to note that all animals treated with OSCS-contaminated heparin showed evidence of kallikrein activation in vivo, even in the absence of clinical signs. Patients undergoing dialysis who are also receiving heparin therapy are already at high risk for hypotension because of their exposure to the dialysis membrane, which can also activate the contact system, and their treatment with angiotensin-converting–enzyme inhibitors, which inhibit bradykinin degradation. Exposure to OSCS-contaminated heparin may further increase the risk and could potentially trigger an adverse event. Finally, these findings also suggest that a simple in vitro bioassay could complement the previously described analytic tests4 to help protect the global supply chain of heparin, by allowing the screening of heparin lots for the presence not only of OSCS but also of other polysulfated contaminants that may have unintended pharmacologic consequences.
Supported by grants from the National Institute of General Medical Sciences and the National Heart and Lung Institute (GM57073 and HL080278-01, respectively, to Dr. Sasisekharan).
Drs. Kishimoto, Ganguly, Lansing, Zhao, Galcheva-Gargova, Roy, Shriver, and Venkataraman, Mr. Smith, and Mr. Baily report being employees of Momenta Pharmaceuticals and holding equity in the company, which has technology on the analysis and characterization of complex mixtures, including heparin. Drs. Sasisekharan and Langer report receiving consulting fees from Scientific Protein Labs and Momenta Pharmaceuticals and holding equity in Momenta Pharmaceuticals. Dr. Austen reports receiving consulting fees from Momenta Pharmaceuticals.
No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0803200) was published at www.nejm.org on April 23, 2008.
We thank Dr. Allen P. Kaplan for helpful discussions; Pete Jobst, Animal Resource Manager, and Andrea Aman, Animal Care Technician, at the Virginia–Maryland Regional College of Veterinary Medicine for their excellent technical help during the in vivo experiments; and Ms. Alison Long, Mr. Chris Honan, Dr. Cedric Hubeau, Mr. Erick Moy, and the staff of the Massachusetts Institute of Technology Division of Comparative Medicine for help with the animal studies.
Source Information
From Momenta Pharmaceuticals (T.K.K., T.G., S.S., J.C.L., G.Z., Z.G.-G., G.S.B., S.R., Z.S., G.V.), the Harvard–Massachusetts Institute of Technology Division of Health Sciences and Technology, Koch Institute for Integrative Cancer Research (K.V., Z.S., R.S.L., G.V., R.S.), and the Massachusetts Institute of Technology (M.W., J.F.) — all in Cambridge, MA; Virginia–Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg (S.E., K.P., N.S., T.R.-C.); the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (A.A.-H., B.F., L.B., M.N., G.J.D.P., J.W.); and Brigham and Women's Hospital and Harvard Medical School, Boston (K.F.A.).
Address reprint requests to Dr. Sasisekharan at the Department of Biological Engineering, Harvard–MIT Division of Health Sciences and Technology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Ave., 16-561, Cambridge, MA 02139, or at rams@mit.edu.
- References
References
1
Acute allergic-type reactions among patients undergoing hemodialysis -- multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 2008;57:124-125
Medline2
Information on adverse event reports and heparin. Rockville, MD: Food and Drug Administration, 2008. (Accessed May 12, 2008, at http://www.fda.gov/cder/drug/infopage/heparin/adverse_events.htm.)
3
Information on heparin sodium injection. Rockville, MD: Food and Drug Administration, 2008. (Accessed May 12, 2008, at http://www.fda.gov/cder/drug/infopage/heparin/default.htm#screening.)
4
Guerrini M, Beccati D, Shriver Z, et al. Oversulfated chondroitin sulfate is a major contaminant in heparin associated with adverse clinical events. Nat Biotechnol (in press).
5
Hojima Y ,Cochrane CG ,Wiggins RC ,Austen KF ,Stevens RL . In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 1984;63:1453-1459
Web of Science | Medline6
Henry SP ,Giclas PC ,Leeds J , et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997;281:810-816
Web of Science | Medline7
Silverberg M ,Diehl SV . The autoactivation of factor XII (Hageman factor) induced by low-Mr heparin and dextran sulphate: the effect of the Mr of the activating polyanion. Biochem J 1987;248:715-720
Web of Science | Medline8
Baxter provides update on the heparin investigation. Deerfield, IL: Baxter, March 19, 2008. (Accessed May 12, 2008, at http://www.baxter.com/products/biopharmaceuticals/downloads/heparin_03-19-08.pdf.)
9
Silverberg M ,Dunn JT ,Garen L ,Kaplan AP . Autoactivation of human Hageman factor: demonstration utilizing a synthetic substrate. J Biol Chem 1980;255:7281-7286
Web of Science | Medline10
Verhamme IM ,Bock PE ,Jackson CM . The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II. J Biol Chem 2004;279:9785-9795
CrossRef | Web of Science | Medline11
Stead N ,Kaplan AP ,Rosenberg RD . Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 1976;251:6481-6488
Web of Science | Medline12
Olson ST ,Sheffer R ,Francis AM . High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein. Biochemistry 1993;32:12136-12147
CrossRef | Web of Science | Medline13
Pixley RA ,Cassello A ,De La Cadena RA ,Kaufman N ,Colman RW . Effect of heparin on the activation of factor XII and the contact system in plasma. Thromb Haemost 1991;66:540-547
Web of Science | Medline14
Kaplan AP ,Austen KF . A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 1971;133:696-712
CrossRef | Web of Science | Medline15
Ghebrehiwet B ,Silverberg M ,Kaplan AP . Activation of the classical pathway of complement by Hageman factor frag-ment. J Exp Med 1981;153:665-676
CrossRef | Web of Science | Medline16
DiScipio RG . The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982;45:587-595
Web of Science | Medline17
Wiggins RC ,Giclas PC ,Henson PM . Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med 1981;153:1391-1404
CrossRef | Web of Science | Medline18
Schaiff WT ,Eisenberg PR . Direct induction of complement activation by pharmacologic activation of plasminogen. Coron Artery Dis 1997;8:9-18
CrossRef | Web of Science | Medline19
Wiggins RC . A different cleavage site for high molecular weight kininogen in vivo following intravenous injection of dextran sulfate in the rabbit. Circ Res 1986;58:595-604
Web of Science | Medline20
Siebeck M ,Cheronis JC ,Fink E , et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol 1994;77:2675-2680
Web of Science | Medline
- Citing Articles (142)
Citing Articles
1
Donatella Cimini, Mario De Rosa, Chiara Schiraldi. (2012) Production of glucuronic acid-based polysaccharides by microbial fermentation for biomedical applications. Biotechnology Journal 7:2, 237-250
CrossRef2
Marc Cohen, Walter P. Jeske, Jose C. Nicolau, Gilles Montalescot, Jawed Fareed. (2012) US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins. Journal of Thrombosis and Thrombolysis
CrossRef3
Ujjwal Bhaskar, Eric Sterner, Anne Marie Hickey, Akihiro Onishi, Fuming Zhang, Jonathan S. Dordick, Robert J. Linhardt. (2012) Engineering of routes to heparin and related polysaccharides. Applied Microbiology and Biotechnology 93:1, 1-16
CrossRef4
Thomas Renné. (2012) The procoagulant and proinflammatory plasma contact system. Seminars in Immunopathology 34:1, 31-41
CrossRef5
Jeffrey J. Sands, Peter Kotanko, Jonathan H. Segal, Chiang-Hong Ho, Len Usvat, Amy Young, Mary Carter, Olga Sergeyeva, Lisa Korth, Eileen Maunsell, Yueping Zhu, Mahesh Krishnan, Jose A. Diaz-Buxo. (2012) Effects of Citrate Acid Concentrate (Citrasate®) on Heparin N Requirements and Hemodialysis Adequacy: A Multicenter, Prospective Noninferiority Trial. Blood Purification 33:1-3, 199-204
CrossRef6
Andrew Erdman, James Nickas, Benton Brown. 2011. Safety of Biotherapeutics. , 585-601.
CrossRef7
Zhenyu Wang, Jennifer Li, Samantha Cheong, Ujjwal Bhaskar, Onishi Akihiro, Fuming Zhang, Jonathan S. Dordick, Robert J. Linhardt. (2011) Response surface optimization of the heparosan N-deacetylation in producing bioengineered heparin. Journal of Biotechnology 156:3, 188-196
CrossRef8
Guy Young. (2011) Old and new antithrombotic drugs in neonates and infants. Seminars in Fetal and Neonatal Medicine 16:6, 349-354
CrossRef9
Guy Young, Donald L. Yee, Sarah H. O'Brien, Rachna Khanna, April Barbour, Diane J. Nugent. (2011) FondaKIDS: A prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatric Blood & Cancer 57:6, 1049-1054
CrossRef10
Vitor H. Pomin. 2011. Structure and Use of Algal Sulfated Fucans and Galactans. , 229-261.
CrossRef11
J. Timothy King, Umesh R. Desai. (2011) Linear polyalkylamines as fingerprinting agents in capillary electrophoresis of low-molecular-weight heparins and glycosaminoglycans. ELECTROPHORESIS 32:21, 3070-3077
CrossRef12
Fuming Zhang, Bo Yang, Mellisa Ly, Kemal Solakyildirim, Zhongping Xiao, Zhenyu Wang, Julie M. Beaudet, Amanda Y. Torelli, Jonathan S. Dordick, Robert J. Linhardt. (2011) Structural characterization of heparins from different commercial sources. Analytical and Bioanalytical Chemistry 401:9, 2793-2803
CrossRef13
J. E. Turnbull. (2011) Getting the Farm Out of Pharma for Heparin Production. Science 334:6055, 462-463
CrossRef14
Udayanath Aich, Zachary Shriver, Kannan Tharakaraman, Rahul Raman, Ram Sasisekharan. (2011) Competitive Inhibition of Heparinase by Persulfonated Glycosaminoglycans: A Tool to Detect Heparin Contamination. Analytical Chemistry 83:20, 7815-7822
CrossRef15
Derek J. Langeslay, Szabolcs Beni, Cynthia K. Larive. (2011) Detection of the 1 H and 15 N NMR Resonances of Sulfamate Groups in Aqueous Solution: A New Tool for Heparin and Heparan Sulfate Characterization. Analytical Chemistry 83:20, 8006-8010
CrossRef16
Andrew Davenport. (2011) Using dialysis machine technology to reduce intradialytic hypotension. Hemodialysis International 15, S37-S42
CrossRef17
Andrew Davenport. (2011) Optimization of heparin anticoagulation for hemodialysis. Hemodialysis International 15, S43-S48
CrossRef18
Rami A. Al-Horani, Aiye Liang, Umesh R. Desai. (2011) Designing Nonsaccharide, Allosteric Activators of Antithrombin for Accelerated Inhibition of Factor Xa. Journal of Medicinal Chemistry 54:17, 6125-6138
CrossRef19
N. Montpas, A. Désormeaux, D. Keire, A. Adam. (2011) Les réactions anaphylactoïdes associées à l’héparine d’origine chinoise. Annales Pharmaceutiques Françaises 69:5, 258-264
CrossRef20
A.J. Chmielewski, F.E. Stanley, A.M. Stalcup. (2011) The use of SAX-HPLC–CD as a heparin screening strategy. Journal of Chromatography B 879:25, 2619-2623
CrossRef21
Qingda Zang, David A. Keire, Lucinda F. Buhse, Richard D. Wood, Dinesh P. Mital, Syed Haque, Shankar Srinivasan, Christine M. V. Moore, Moheb Nasr, Ali Al-Hakim, Michael L. Trehy, William J. Welsh. (2011) Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data. Analytical and Bioanalytical Chemistry 401:3, 939-955
CrossRef22
Kyohei Higashi, Mellisa Ly, Zhenyu Wang, Sayaka Masuko, Ujjwal Bhaskar, Eric Sterner, Fuming Zhang, Toshihiko Toida, Jonathan S. Dordick, Robert J. Linhardt. (2011) Controlled photochemical depolymerization of K5 heparosan, a bioengineered heparin precursor. Carbohydrate Polymers 86:3, 1365-1370
CrossRef23
Michiko Tajiri, Yoshinao Wada. (2011) Infrared matrix-assisted laser desorption/ionization mass spectrometry for quantification of glycosaminoglycans and gangliosides. International Journal of Mass Spectrometry 305:2-3, 164-169
CrossRef24
Andrew Davenport. (2011) What are the anticoagulation options for intermittent hemodialysis?. Nature Reviews Nephrology
CrossRef25
Zhenyu Wang, Bo Yang, Zhenqing Zhang, Mellisa Ly, Majde Takieddin, Shaker Mousa, Jian Liu, Jonathan S. Dordick, Robert J. Linhardt. (2011) Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Applied Microbiology and Biotechnology 91:1, 91-99
CrossRef26
J. K. Lee, P. Vadas. (2011) Anaphylaxis: mechanisms and management. Clinical & Experimental Allergy 41:7, 923-938
CrossRef27
Jiancheng Chen, Shuhei Yamada, Yoshiki Hama, Ajaya Kumar Shetty, Takanari Kobayashi, Hiroshi Oda, Kosuke Seiki, Eunmi Kim, Takashi Kimura, Naonori Takahashi, Kazuya I.P.J. Hidari, Takashi Suzuki, Yasuo Suzuki, Kazuyuki Sugahara. (2011) Unique heparan sulfate from shrimp heads exhibits a strong inhibitory effect on infections by dengue virus and Japanese encephalitis virus. Biochemical and Biophysical Research Communications
CrossRef28
Catia Argenta, Maria Angélica Pires Ferreira, Guilherme Becker Sander, Leila Beltrami Moreira. (2011) Short-Term Therapy with Enoxaparin or Unfractionated Heparin for Venous Thromboembolism in Hospitalized Patients: Utilization Study and Cost-Minimization Analysis. Value in Health 14:5, S89-S92
CrossRef29
A. Corbier, N. Le Berre, D. Rampe, H. Meng, M. Lorenz, P. Vicat, S. Potdevin, M. Doubovetzky. (2011) Oversulfated Chondroitin Sulfate and OSCS-Contaminated Heparin Cause Dose- and Route-Dependent Hemodynamic Effects in the Rat. Toxicological Sciences 121:2, 417-427
CrossRef30
Richard A. McPherson, Aileen G. Buckler, Kimberly W. Sanford, Susan D. Roseff. (2011) Investigation of heparin-related hypotensive adverse events during photopheresis: utility of a patient care database. Transfusion 51:6, 1314-1320
CrossRef31
Ulrike Holzgrabe, Myriam Malet-Martino. (2011) Analytical challenges in drug counterfeiting and falsification—The NMR approach. Journal of Pharmaceutical and Biomedical Analysis 55:4, 679-687
CrossRef32
Youngjea Kang, Kihak Gwon, Jae Ho Shin, Hakhyun Nam, Mark E. Meyerhoff, Geun Sig Cha. (2011) Highly Sensitive Potentiometric Strip Test for Detecting High Charge Density Impurities in Heparin. Analytical Chemistry 83:10, 3957-3962
CrossRef33
Guoxiang Chen, Kiyoshi Fujimori, Hans Lee, Yasser Nashed-Samuel, Joseph Phillips, Gary Rogers, Hong Shen, Chanel Yee. (2011) Detection of adulteration in acetonitrile. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 78:5, 1646-1650
CrossRef34
Qingda Zang, David A. Keire, Richard D. Wood, Lucinda F. Buhse, Christine M.V. Moore, Moheb Nasr, Ali Al-Hakim, Michael L. Trehy, William J. Welsh. (2011) Combining 1H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants. Journal of Pharmaceutical and Biomedical Analysis 54:5, 1020-1029
CrossRef35
Guy Young. (2011) New anticoagulants in children: A review of recent studies and a look to the future. Thrombosis Research 127:2, 70-74
CrossRef36
Chris Oschatz, Coen Maas, Bernd Lecher, Thomas Jansen, Jenny Björkqvist, Thomas Tradler, Reinhard Sedlmeier, Peter Burfeind, Sven Cichon, Sven Hammerschmidt, Werner Müller-Esterl, Walter A. Wuillemin, Gunnar Nilsson, Thomas Renné. (2011) Mast Cells Increase Vascular Permeability by Heparin-Initiated Bradykinin Formation In Vivo. Immunity 34:2, 258-268
CrossRef37
F. Estelle R. Simons, Ledit R. F. Ardusso, M. Beatrice Bilò, Yehia M. El-Gamal, Dennis K. Ledford, Johannes Ring, Mario Sanchez-Borges, Gian Enrico Senna, Aziz Sheikh, Bernard Y. Thong. (2011) World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis. World Allergy Organization Journal 4:2, 13-36
CrossRef38
Timothy R. Rudd, Davide Gaudesi, Mark A. Skidmore, Monica Ferro, Marco Guerrini, Barbara Mulloy, Giangiacomo Torri, Edwin A. Yates. (2011) Construction and use of a library of bona fide heparins employing 1H NMR and multivariate analysis. The Analyst 136:7, 1380
CrossRef39
Guilherme L. Sassaki, Daniel S. Riter, Arquimedes P. Santana Filho, Marco Guerrini, Marcelo A. Lima, Cesare Cosentino, Lauro M. Souza, Thales R. Cipriani, Timothy R. Rudd, Helena B. Nader, Edwin A. Yates, Philip A. J. Gorin, Giangiacomo Torri, Marcello Iacomini. (2011) A robust method to quantify low molecular weight contaminants in heparin: detection of tris(2-n-butoxyethyl) phosphate. The Analyst 136:11, 2330
CrossRef40
S. RANGARAJAN. (2011) Inhibitors of coagulation. Haemophilia 17:1, 90-94
CrossRef41
F. E. Stanley, A. M. Stalcup. (2011) The use of circular dichroism as a simple heparin-screening strategy. Analytical and Bioanalytical Chemistry 399:2, 701-706
CrossRef42
E. Kellenbach, K. Sanders, P. J. A. Michiels, F. C. Girard. (2011) 1H NMR signal at 2.10 ppm in the spectrum of KMnO4-bleached heparin sodium: identification of the chemical origin using an NMR-only approach. Analytical and Bioanalytical Chemistry 399:2, 621-628
CrossRef43
Timothy R. Rudd, Davide Gaudesi, Marcelo A. Lima, Mark A. Skidmore, Barbara Mulloy, Giangiacomo Torri, Helena B. Nader, Marco Guerrini, Edwin A. Yates. (2011) High-sensitivity visualisation of contaminants in heparin samples by spectral filtering of 1H NMR spectra. The Analyst 136:7, 1390
CrossRef44
Sarah E. Lee, Edward K. Chess, Barrett Rabinow, G. Joseph Ray, Christina M. Szabo, Bennett Melnick, Reagan L. Miller, Lakshmy M. Nair, Edwin G. Moore. (2011) NMR of heparin API: investigation of unidentified signals in the USP-specified range of 2.12–3.00 ppm. Analytical and Bioanalytical Chemistry 399:2, 651-662
CrossRef45
Vy M. Tran, Thao K. N. Nguyen, Karthik Raman, Balagurunathan Kuberan. (2011) Applications of isotopes in advancing structural and functional heparanomics. Analytical and Bioanalytical Chemistry 399:2, 559-570
CrossRef46
Susanne Lühn, Simone Schiemann, Susanne Alban. (2011) Simple fluorescence assay for quantification of OSCS in heparin. Analytical and Bioanalytical Chemistry 399:2, 673-680
CrossRef47
Shigeru Amemiya, Yushin Kim, Ryoichi Ishimatsu, Benjamin Kabagambe. (2011) Electrochemical heparin sensing at liquid/liquid interfaces and polymeric membranes. Analytical and Bioanalytical Chemistry 399:2, 571-579
CrossRef48
Zhenling Liu, Zhongping Xiao, Sayaka Masuko, Wenjing Zhao, Eric Sterner, Vinod Bansal, Jawed Fareed, Jonathan Dordick, Fuming Zhang, Robert J. Linhardt. (2011) Mass balance analysis of contaminated heparin product. Analytical Biochemistry 408:1, 147-156
CrossRef49
Szabolcs Beni, John F. K. Limtiaco, Cynthia K. Larive. (2011) Analysis and characterization of heparin impurities. Analytical and Bioanalytical Chemistry 399:2, 527-539
CrossRef50
Mellisa Ly, Zhenyu Wang, Tatiana N. Laremore, Fuming Zhang, Weihong Zhong, Dennis Pu, Dmitri V. Zagorevski, Jonathan S. Dordick, Robert J. Linhardt. (2011) Analysis of E. coli K5 capsular polysaccharide heparosan. Analytical and Bioanalytical Chemistry 399:2, 737-745
CrossRef51
John Beirne, Hilary Truchan, Lin Rao. (2011) Development and qualification of a size exclusion chromatography coupled with multiangle light scattering method for molecular weight determination of unfractionated heparin. Analytical and Bioanalytical Chemistry 399:2, 717-725
CrossRef52
David A. Keire, Hongping Ye, Michael L. Trehy, Wei Ye, Richard E. Kolinski, Benjamin J. Westenberger, Lucinda F. Buhse, Moheb Nasr, Ali Al-Hakim. (2011) Characterization of currently marketed heparin products: key tests for quality assurance. Analytical and Bioanalytical Chemistry 399:2, 581-591
CrossRef53
M. Martin, H. Ott, H.F. Merk, B. Sachs. (2011) Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity reactions to contaminated heparins. British Journal of Dermatology 164:1, 68-75
CrossRef54
Zhenyu Wang, Mellisa Ly, Fuming Zhang, Weihong Zhong, Amy Suen, Anne Marie Hickey, Jonathan S. Dordick, Robert J. Linhardt. (2010) E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnology and Bioengineering 107:6, 964-973
CrossRef55
Robert C. Pendleton, George M. Rodgers, Russell D. Hull. (2010) Established Venous Thromboembolism Therapies: Heparin, Low Molecular Weight Heparins, and Vitamin K Antagonists, with a Discussion of Heparin-Induced Thrombocytopenia. Clinics in Chest Medicine 31:4, 691-706
CrossRef56
Scott M. Stevens, James D. Douketis. (2010) Deep Vein Thrombosis Prophylaxis in Hospitalized Medical Patients: Current Recommendations, General Rates of Implementation, and Initiatives for Improvement. Clinics in Chest Medicine 31:4, 675-689
CrossRef57
Tanja Beyer, Bernd Diehl, Ulrike Holzgrabe. (2010) Quantitative NMR spectroscopy of biologically active substances and excipients. Bioanalytical Reviews 2:1-4, 1-22
CrossRef58
J. Dernedde, A. Rausch, M. Weinhart, S. Enders, R. Tauber, K. Licha, M. Schirner, U. Zugel, A. von Bonin, R. Haag. (2010) Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation. Proceedings of the National Academy of Sciences 107:46, 19679-19684
CrossRef59
(2010) Drug Allergy: An Updated Practice Parameter. Annals of Allergy, Asthma & Immunology 105:4, 259-273.e78
CrossRef60
Daniela Beccati, Sucharita Roy, Fei Yu, Nur Sibel Gunay, Ishan Capila, Miroslaw Lech, Robert J. Linhardt, Ganesh Venkataraman. (2010) Identification of a novel structure in heparin generated by potassium permanganate oxidation. Carbohydrate Polymers 82:3, 699-705
CrossRef61
Brian L. Henry, Umesh R. Desai. 2010. Anticoagulants. .
CrossRef62
Phillip Lieberman, Richard A. Nicklas, John Oppenheimer, Stephen F. Kemp, David M. Lang, David I. Bernstein, Jonathan A. Bernstein, A. Wesley Burks, Anna M. Feldweg, Jordan N. Fink, Paul A. Greenberger, David B.K. Golden, John M. James, Stephen F. Kemp, Dennis K. Ledford, Phillip Lieberman, Albert L. Sheffer, David I. Bernstein, Joann Blessing-Moore, Linda Cox, David A. Khan, David Lang, Richard A. Nicklas, John Oppenheimer, Jay M. Portnoy, Christopher Randolph, Diane E. Schuller, Sheldon L. Spector, Stephen Tilles, Dana Wallace. (2010) The diagnosis and management of anaphylaxis practice parameter: 2010 Update. Journal of Allergy and Clinical Immunology 126:3, 477-480.e42
CrossRef63
Ann W. McMahon, Robert G. Pratt, Tarek A. Hammad, Steven Kozlowski, Esther Zhou, Susan Lu, Corrinne G. Kulick, Tarun Mallick, Gerald Dal Pan. (2010) Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008. Pharmacoepidemiology and Drug Safety 19:9, 921-933
CrossRef64
David A. Keire, Daniel J. Mans, Hongping Ye, Richard E. Kolinski, Lucinda F. Buhse. (2010) Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches. Journal of Pharmaceutical and Biomedical Analysis 52:5, 656-664
CrossRef65
Edward P. Feener. (2010) Plasma Kallikrein and Diabetic Macular Edema. Current Diabetes Reports 10:4, 270-275
CrossRef66
S. Schulman. (2010) New aspects on treatment modalities for thromboembolic episodes. Journal of Internal Medicine 268:2, 109-119
CrossRef67
V. Meyer, S.W. Schneider, T. Görge. (2010) Antikoagulation in der Dermatologie. Der Hautarzt 61:8, 705-718
CrossRef68
Vy M. Tran, Xylophone V. Victor, James W. Yockman, Balagurunathan Kuberan. (2010) RGD-xyloside conjugates prime glycosaminoglycans. Glycoconjugate Journal 27:6, 625-633
CrossRef69
Ulrike Holzgrabe. (2010) Quantitative NMR spectroscopy in pharmaceutical applications. Progress in Nuclear Magnetic Resonance Spectroscopy 57:2, 229-240
CrossRef70
Albert Adam, Nicolas Montpas, David Keire, Anik Désormeaux, Nancy J. Brown, François Marceau, Benjamin Westenberger. (2010) Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 31:22, 5741-5748
CrossRef71
Axel Trautmann, Cornelia S. Seitz. (2010) The Complex Clinical Picture of Side Effects to Anticoagulation. Medical Clinics of North America 94:4, 821-834
CrossRef72
M. SCHINDEWOLF, H. KROLL, H. ACKERMANN, J. GARBARAVICIENE, R. KAUFMANN, W.-H. BOEHNCKE, R. J. LUDWIG, E. LINDHOFF-LAST. (2010) Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis 8:7, 1486-1491
CrossRef73
Tanja Beyer, Magnus Matz, Daniela Brinz, Oliver Rädler, Bernhard Wolf, Jochen Norwig, Knut Baumann, Susanne Alban, Ulrike Holzgrabe. (2010) Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market. European Journal of Pharmaceutical Sciences 40:4, 297-304
CrossRef74
M. Moia, S. Braham. (2010) Nuovi farmaci antitrombotici in chirurgia ortopedica: dagli studi clinici all’uso nella pratica quotidiana. Archivio di Ortopedia e Reumatologia 121:1, 32-35
CrossRef75
Martin N. Montoro. 2010. Venous Thromboembolism and Inherited Thrombophilias. , 117-126.
CrossRef76
Daniel J. Cushing, Warren D. Cooper, Marlene L. Cohen, Julie R.S. McVoy, Michael Sobel, Robert B. Harris. (2010) Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist. European Journal of Pharmacology 635:1-3, 165-170
CrossRef77
Jing Pan, Yi Qian, Xiaodong Zhou, Andrew Pazandak, Sarah B Frazier, Peter Weiser, Hong Lu, Lijuan Zhang. (2010) Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nature Biotechnology 28:3, 203-207
CrossRef78
Evi Stavrou, Alvin H. Schmaier. (2010) Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thrombosis Research 125:3, 210-215
CrossRef79
(2010) Reply to Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nature Biotechnology 28:3, 207-211
CrossRef80
David A. Keire, Michael L. Trehy, John C. Reepmeyer, Richard E. Kolinski, Wei Ye, Jamie Dunn, Benjamin J. Westenberger, Lucinda F. Buhse. (2010) Analysis of crude heparin by 1H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate. Journal of Pharmaceutical and Biomedical Analysis 51:4, 921-926
CrossRef81
Esther Wenk, Amanda R. Murphy, David L. Kaplan, Lorenz Meinel, Hans P. Merkle, Lorenz Uebersax. (2010) The use of sulfonated silk fibroin derivatives to control binding, delivery and potency of FGF-2 in tissue regeneration. Biomaterials 31:6, 1403-1413
CrossRef82
Gowthami M. Arepally, Thomas L. Ortel. (2010) Heparin-Induced Thrombocytopenia. Annual Review of Medicine 61:1, 77-90
CrossRef83
Aaron D. Baldwin, Kristi L. Kiick. (2010) Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers 94:1, 128-140
CrossRef84
Vitor H. Pomin. (2010) Structural and functional insights into sulfated galactans: a systematic review. Glycoconjugate Journal 27:1, 1-12
CrossRef85
Richard A. Ward, George R. Aronoff. (2010) Recognizing and Reacting to Product-Related Adverse Events in Hemodialysis. American Journal of Kidney Diseases 55:1, 11-14
CrossRef86
Zhenqing Zhang, Boyangzi Li, Jiraporn Suwan, Fuming Zhang, Zhenyu Wang, Haiying Liu, Barbara Mulloy, Robert J. Linhardt. (2009) Analysis of pharmaceutical heparins and potential contaminants using 1 H-NMR and PAGE. Journal of Pharmaceutical Sciences 98:11, 4017-4026
CrossRef87
M. Guerrini, Z. Zhang, Z. Shriver, A. Naggi, S. Masuko, R. Langer, B. Casu, R. J. Linhardt, G. Torri, R. Sasisekharan. (2009) Orthogonal analytical approaches to detect potential contaminants in heparin. Proceedings of the National Academy of Sciences 106:40, 16956-16961
CrossRef88
F. Estelle R. Simons. (2009) Anaphylaxis: Recent advances in assessment and treatment. Journal of Allergy and Clinical Immunology 124:4, 625-636
CrossRef89
John A. Spencer, John F. Kauffman, John C. Reepmeyer, Connie M. Gryniewicz, Wei Ye, Duckhee Y. Toler, Lucinda F. Buhse, Benjamin J. Westenberger. (2009) Screening of heparin API by near infrared reflectance and Raman spectroscopy. Journal of Pharmaceutical Sciences 98:10, 3540-3547
CrossRef90
Matthew D. Mitchell, Barbara Jo Anderson, Kendal Williams, Craig A. Umscheid. (2009) Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review. Journal of Advanced Nursing 65:10, 2007-2021
CrossRef91
Andrew Davenport. (2009) Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis. American Journal of Kidney Diseases 54:2, 361-374
CrossRef92
Axel Trautmann, Cornelia S. Seitz. (2009) Heparin Allergy: Delayed-Type Non–IgE-Mediated Allergic Hypersensitivity to Subcutaneous Heparin Injection. Immunology and Allergy Clinics of North America 29:3, 469-480
CrossRef93
Eleni Papakonstantinou, George Karakiulakis. (2009) The ‘sweet’ and ‘bitter’ involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance. British Journal of Pharmacology 157:7, 1111-1127
CrossRef94
Martijn F.B.G. Gebbink, Barend Bouma, Coen Maas, Bonno N. Bouma. (2009) Physiological responses to protein aggregates: Fibrinolysis, coagulation and inflammation (new roles for old factors). FEBS Letters 583:16, 2691-2699
CrossRef95
Jenson Verghese, Aiye Liang, Preet Pal Singh Sidhu, Michael Hindle, Qibing Zhou, Umesh R. Desai. (2009) First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor Xa. Bioorganic & Medicinal Chemistry Letters 19:15, 4126-4129
CrossRef96
Vitor H. Pomin. (2009) Review: An overview about the structure-function relationship of marine sulfated homopolysaccharides with regular chemical structures. Biopolymers 91:8, 601-609
CrossRef97
Marc Nicolai Busche, Tina Peters, Karsten Knobloch, Peter Maria Vogt, Hans-Oliver Rennekampff. (2009) Heparin-Induced Thrombocytopenia in a Nonthrombocytopenic Patient With Toxic Epidermal Necrolysis Causing Fatal Outcome: Is HIT Still a HIT?. Journal of Burn Care & Research 30:4, 747-751
CrossRef98
Jiraporn Suwan, Zhenqing Zhang, Boyangzi Li, Preeyanat Vongchan, Puttinan Meepowpan, Fuming Zhang, Shaker A. Mousa, Shaymaa Mousa, Bhusana Premanode, Prachya Kongtawelert, Robert J. Linhardt. (2009) Sulfonation of papain-treated chitosan and its mechanism for anticoagulant activity. Carbohydrate Research 344:10, 1190-1196
CrossRef99
Nicola Volpi, Francesca Maccari, Robert J. Linhardt. (2009) Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations. Analytical Biochemistry 388:1, 140-145
CrossRef100
A. Désormeaux, N. Montpas, A. Adam. (2009) Les réactions d’hypersensibilité associées à l’injection intraveineuse d’héparine d’origine chinoise. Annales Pharmaceutiques Françaises 67:3, 169-172
CrossRef101
Toshihiko Toida, Kenji Sato, Noriko Sakamoto, Shinobu Sakai, Saori Hosoyama, Robert J. Linhardt. (2009) Solvolytic depolymerization of chondroitin and dermatan sulfates. Carbohydrate Research 344:7, 888-893
CrossRef102
Aiye Liang, Arjun Raghuraman, Umesh R. Desai. (2009) Capillary electrophoretic study of small, highly sulfated, non-sugar molecules interacting with antithrombin. ELECTROPHORESIS 30:9, 1544-1551
CrossRef103
Peter Bigler, Rudolf Brenneisen. (2009) Improved impurity fingerprinting of heparin by high resolution 1H NMR spectroscopy. Journal of Pharmaceutical and Biomedical Analysis 49:4, 1060-1064
CrossRef104
Atsuhiko Wada, Shun-ichi Tamaru, Masato Ikeda, Itaru Hamachi. (2009) MCM−Enzyme−Supramolecular Hydrogel Hybrid as a Fluorescence Sensing Material for Polyanions of Biological Significance. Journal of the American Chemical Society 131:14, 5321-5330
CrossRef105
Michael L. Trehy, John C. Reepmeyer, Richard E. Kolinski, Benjamin J. Westenberger, Lucinda F. Buhse. (2009) Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. Journal of Pharmaceutical and Biomedical Analysis 49:3, 670-673
CrossRef106
K. Sauer, J. Steczko, S. R. Ash. (2009) Effect of a solution containing citrate/Methylene Blue/parabens on Staphylococcus aureus bacteria and biofilm, and comparison with various heparin solutions. Journal of Antimicrobial Chemotherapy 63:5, 937-945
CrossRef107
Matthias Orth. (2009) Factor II- and factor Xa-inhibitors for prevention and treatment of thromboses / Faktor II- und Faktor Xa-Inhibitoren in der Prävention und Therapie von Thrombosen. LaboratoriumsMedizin 33:2, 121-127
CrossRef108
Jerrold H. Levy, Kenichi A. Tanaka. (2009) Anticoagulation and Reversal Paradigms: Is Too Much of a Good Thing Bad?. Anesthesia & Analgesia 108:3, 692-694
CrossRef109
P.-J. Bousquet, P. Demoly, A. Romano. (2009) Drug allergy and hypersensitivity: still a hot topic. Allergy 64:2, 179-182
CrossRef110
Antonio Peramo, Mark B. Meads, William S. Dalton, W. Garrett Matthews. (2009) Polymer model of cancer cell adhesion to glycosaminoglycan substrates using the radius of gyration. Journal of Applied Polymer Science 111:1, 70-77
CrossRef111
Robert M. Lauder. (2009) Chondroitin sulphate: A complex molecule with potential impacts on a wide range of biological systems. Complementary Therapies in Medicine 17:1, 56-62
CrossRef112
Naotaka KAKOI, Mitsuhiro KINOSHITA, Nana KAWASAKI, Teruhide YAMAGUCHI, Takao HAYAKAWA, Kazuaki KAKEHI. (2009) Capillary Electrophoresis Analysis of Contaminants in Heparin Sodium for the Japanese Pharmacopoeia Purity Test. YAKUGAKU ZASSHI 129:10, 1255-1264
CrossRef113
Haiying Liu, Zhenqing Zhang, Robert J. Linhardt. (2009) Lessons learned from the contamination of heparin. Natural Product Reports 26:3, 313
CrossRef114
Sherket Peterson, Amber Frick, Jian Liu. (2009) Design of biologically active heparan sulfate and heparin using an enzyme-based approach. Natural Product Reports 26:5, 610
CrossRef115
Rainer Domanig, Wolfgang Jöbstl, Silvia Gruber, Thomas Freudemann. (2009) One-dimensional cellulose acetate plate electrophoresis—A feasible method for analysis of dermatan sulfate and other glycosaminoglycan impurities in pharmaceutical heparin. Journal of Pharmaceutical and Biomedical Analysis 49:1, 151-155
CrossRef116
Colin Longstaff, Colin M. Whitton, Richard Stebbings, Elaine Gray. (2009) How do we assure the quality of biological medicines?. Drug Discovery Today 14:1-2, 50-55
CrossRef117
Nana Kawasaki, Satsuki Itoh, Noritaka Hashii, Daisuke Takakura, Yan Qin, Xiaoyu Huang, Teruhide Yamaguchi. (2009) The Significance of Glycosylation Analysis in Development of Biopharmaceuticals. Biological & Pharmaceutical Bulletin 32:5, 796-800
CrossRef118
Albert K. Korir, Cynthia K. Larive. (2009) Advances in the separation, sensitive detection, and characterization of heparin and heparan sulfate. Analytical and Bioanalytical Chemistry 393:1, 155-169
CrossRef119
Joshua G Schier, Carol S Rubin, Dorothy Miller, Dana Barr, Michael A McGeehin. (2009) Medication-associated diethylene glycol mass poisoning: A review and discussion on the origin of contamination. Journal of Public Health Policy 30:2, 127-143
CrossRef120
Blossom, David B., Kallen, Alexander J., Patel, Priti R., Elward, Alexis, Robinson, Luke, Gao, Ganpan, Langer, Robert, Perkins, Kiran M., Jaeger, Jennifer L., Kurkjian, Katie M., Jones, Marilyn, Schillie, Sarah F., Shehab, Nadine, Ketterer, Daniel, Venkataraman, Ganesh, Kishimoto, Takashi Kei, Shriver, Zachary, McMahon, Ann W., Austen, K. Frank, Kozlowski, Steven, Srinivasan, Arjun, Turabelidze, George, Gould, Carolyn V., Arduino, Matthew J., Sasisekharan, Ram, . (2008) Outbreak of Adverse Reactions Associated with Contaminated Heparin. New England Journal of Medicine 359:25, 2674-2684
Full Text121
Alban, Susanne, Lühn, Susanne, . (2008) Prothrombin Time for Detection of Contaminated Heparins. New England Journal of Medicine 359:25, 2732-2734
Full Text122
(2008) Letters to the Editor. Journal of the American Veterinary Medical Association 233:11, 1687-1689
CrossRef123
Cecilia Tami, Montserrat Puig, John C. Reepmeyer, Hongping Ye, D. Andre D'Avignon, Lucinda Buhse, Daniela Verthelyi. (2008) Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. Biomaterials 29:36, 4808-4814
CrossRef124
(2008) Rivaroxaban for Thromboprophylaxis. New England Journal of Medicine 359:20, 2174-2176
Full Text125
Marik, Paul E., Plante, Lauren A., . (2008) Venous Thromboembolic Disease and Pregnancy. New England Journal of Medicine 359:19, 2025-2033
Full Text126
(2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:11, i-xvi
CrossRef127
Antonio Peramo, Mark B. Meads, William S. Dalton, W. Garrett Matthews. (2008) Static adhesion of cancer cells to glass surfaces coated with glycosaminoglycans. Colloids and Surfaces B: Biointerfaces 67:1, 140-144
CrossRef128
Stacie L. Eldridge, Albert K. Korir, Sarah M. Gutierrez, Fernando Campos, John F.K. Limtiaco, Cynthia K. Larive. (2008) Heterogeneity of depolymerized heparin SEC fractions: to pool or not to pool?. Carbohydrate Research 343:17, 2963-2970
CrossRef129
(2008) Heparin contaminant causes adverse effects via the kallikrein system. Nature Clinical Practice Cardiovascular Medicine 5:10, 596-596
CrossRef130
Harold L. Dauerman. (2008) Coronary Intervention Without a Safety Net. Journal of the American College of Cardiology 52:16, 1299-1301
CrossRef131
(2008) Contaminated Heparin. New England Journal of Medicine 359:12, 1291-1293
Full Text132
T. Beyer, B. Diehl, G. Randel, E. Humpfer, H. Schäfer, M. Spraul, C. Schollmayer, U. Holzgrabe. (2008) Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. Journal of Pharmaceutical and Biomedical Analysis 48:1, 13-19
CrossRef133
V. H Pomin, P. A S Mourao. (2008) Structure, biology, evolution, and medical importance of sulfated fucans and galactans. Glycobiology 18:12, 1016-1027
CrossRef134
Alvin H. Schmaier. (2008) The elusive physiologic role of Factor XII. Journal of Clinical Investigation
CrossRef135
Jacyntha A. Sterling. (2008) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 43:8, 676-683
CrossRef136
C. Monneret. (2008) Les héparines contaminées. Annales Pharmaceutiques Françaises 66:4, 212-215
CrossRef137
Coen Maas, José W.P. Govers-Riemslag, Barend Bouma, Bettina Schiks, Bouke P.C. Hazenberg, Henk M. Lokhorst, Per Hammarström, Hugo ten Cate, Philip G. de Groot, Bonno N. Bouma, Martijn F.B.G. Gebbink. (2008) Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. Journal of Clinical Investigation
CrossRef138
Lohrmann, Jens, Becker, Richard C., . (2008) New Anticoagulants — The Path from Discovery to Clinical Practice. New England Journal of Medicine 358:26, 2827-2829
Full Text139
Schwartz, Lawrence B., . (2008) Heparin Comes Clean. New England Journal of Medicine 358:23, 2505-2509
Full Text140
Avorn, Jerry, . (2008) Coagulation and Adulteration — Building on Science and Policy Lessons from 1905. New England Journal of Medicine 358:23, 2429-2431
Full Text141
G. Young. (2008) New Anticoagulants in Children. Hematology 2008:1, 245-250
CrossRef142
Hideyuki YAMAGUCHI, Mai SHINAGAWA, Nobuhisa SHIMBA, Hiroshi MIYANO, Eiichiro SUZUKI. (2008) NMR Analysis of a Contaminant in Heparin. YAKUGAKU ZASSHI 128:10, 1513-1515
CrossRef
- Letters
